| Q90335662 | Activation of Innate Immune Responses by a CpG Oligonucleotide Sequence Composed Entirely of Threose Nucleic Acid |
| Q39551385 | Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses. |
| Q50056654 | B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors |
| Q34048170 | B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21 |
| Q42742024 | B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. |
| Q27487859 | Broad-Spectrum Drugs Against Viral Agents |
| Q36140670 | CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway |
| Q38570179 | CpG oligodeoxynucleotides as immunotherapy in cancer. |
| Q36809776 | Development of TLR9 agonists for cancer therapy |
| Q85952940 | Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system |
| Q51901055 | Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. |
| Q31038111 | Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression |
| Q36557953 | Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? |
| Q38298483 | Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells |
| Q37420514 | Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees |
| Q37671216 | Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application |
| Q84639319 | Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help |
| Q45937361 | Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: A Belgian multicentric study. |
| Q34194680 | In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study |
| Q38657642 | In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. |
| Q37159157 | Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo |
| Q56942850 | Inflammation and multiple myeloma: the Toll connection |
| Q35096709 | Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. |
| Q37334965 | Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia |
| Q36758769 | Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment |
| Q34360347 | Mantle cell lymphoma activation enhances bortezomib sensitivity |
| Q56514276 | Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL |
| Q60949513 | Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis |
| Q55427997 | NF-κB signaling and its relevance to the treatment of mantle cell lymphoma. |
| Q37051022 | Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies |
| Q40289625 | Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors |
| Q35949884 | Periodontal bacterial DNA suppresses the immune response to mutans streptococcal glucosyltransferase |
| Q36222910 | Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia |
| Q37354301 | Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma |
| Q37079426 | Phenotypic and functional heterogeneity of human memory B cells |
| Q40057379 | Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs |
| Q33695664 | Short- and long-term changes in gene expression mediated by the activation of TLR9 |
| Q35861964 | TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells |
| Q33760295 | TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells |
| Q36071989 | TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism |
| Q34320769 | TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo |
| Q53595110 | The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. |
| Q34088209 | The C allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and TLR9 up-regulation and confers increased B-cell proliferation |
| Q37422510 | The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma |
| Q36001708 | Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. |
| Q38042942 | Toll-like Receptors in Chronic Lymphocytic Leukemia |
| Q36635059 | Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia |
| Q55006191 | Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma. |
| Q38213432 | Toll-like receptors and B cells: functions and mechanisms |
| Q37051007 | Toll-like receptors and immune regulation: implications for cancer therapy |
| Q38238963 | Toll-like receptors in the pathogenesis of human B cell malignancies |
| Q40291993 | Toll-like receptors mediate proliferation and survival of multiple myeloma cells |
| Q37203723 | Toll-like receptors: lessons to learn from normal and malignant human B cells |
| Q35604586 | X-shaped DNA potentiates therapeutic efficacy in colitis-associated colon cancer through dual activation of TLR9 and inflammasomes |